Purpose: To report the efficacy of the predetermined treatment protocol of the Collaborative Bleb-related Infection Incidence and Treatment Study (CBIITS) for bleb-related infection (BRI) patients. Methods: A prospective, observational cohort study was conducted at 34 clinical centres in Japan. Nineteen eyes from 19 patients that developed BRI were treated using the CBIITS protocol at 34 clinical centres. The visual acuity (VA) and intraocular pressure (IOP) were monitored for 6 and 12 months after treatment with the predetermined protocol. Results: The logMAR was 0.623 AE 0.748 (mean AE standard deviation) before the infection developed. It was 1.054 AE 1.156 and 0.950 AE 1.168 at 6 months and 12 months post-infection, respectively. However, in subgroup analyses, there was no significant decrease in post-infection logMAR in stages I and II. In contrast, decimal VA was decreased ≥2 lines in all four cases in stage III. The IOP did not change after infection. It was 10.2 AE 5.0 mmHg (range, 3-22 mmHg) before the infection developed, and 12.9 AE 5.2 mmHg (5-24 mmHg) and 10.7 AE 4.7 mmHg (3-18 mmHg) at 6 months and 12 months after infection, respectively. Conclusion: Because of the small number of BRI patients, the superiority of the treatment was not definitively determined. However, VA was almost maintained in stages I and II, and the IOP did not change after infection. Although further study is necessary, the treatment protocol shown in the study might be a valuable treatment regime.
Introduction
Bleb-related infection (BRI) is a major complication following glaucoma filtering surgery (Jampel et al. 2012; Yamamoto et al. 2013b; Yassin 2016) that can result in severe visual disturbances (Yamada et al. 2014) , and antibacterial therapy for the infection should be performed as soon as possible in suspected cases. However, an effective treatment protocol has not yet been established. The use of antibacterial therapy and/or the use of varying amounts of drugs depend on the physician's discretion; hence, there is the possibility of insufficient or excessive treatment. The establishment of an adequate and standardized treatment protocol for BRI is therefore necessary.
The Japan Glaucoma Society initiated a prospective study to investigate the incidence, severity, prognoses and efficacy of BRI predetermined antibacterial management protocols (Yamamoto & Kuwayama 2011) . The study was named CBIITS. The CBIITS reported that the 5-year incidence of BRI was 2.2 AE 0.5% (calculated cumulative incidence AEstandard error) and that bleb leakage and younger age were the main risk factors for infection ). The present CBIITS report describes the features and outcomes of BRI during the 5-year follow-up and the efficacy of the predetermined treatment protocol. This immediate intensive treatment involved the use of massive amounts of antibacterial drugs and vitreous surgery, when necessary.
Materials and Methods
The CBIITS details have been previously reported (Yamamoto & Kuwayama 2011; Yamamoto et al. 2014) . Briefly, the CBIITS was a multicentre, prospective cohort study to estimate the incidence of BRI, to identify its risk factors and to determine the outcome of its preset treatment protocol. There were 34 institutions participating in the study. The clinical centres and the investigators are listed in Appendix. Institutional review board approval was obtained at each institution. All study procedures adhered to the Tenets of the Declaration of Helsinki, and all patients gave written informed consent after a thorough explanation of the study.
This study reports the clinical features of BRI and the efficacy of the predetermined CBIITS treatment. As previously reported, BRI was defined in the CBIITS as an infection fulfilling all of the following conditions: a history of filtering surgery, an episode developing no sooner than postoperative 4 weeks and slit-lamp microscopy confirming clinical signs of infection related to a filtering bleb. After confirmation, BRI was classified into the following three stages (Azuara-Blanco & Katz 1998; Greenfield 1998) Additional examinations, including slit-lamp examinations, B-mode echography and microbiological tests, were conducted, and predetermined treatment was immediately initiated, depending on the stage of the infection in cases with BRI. Briefly, for the intrableb infection, 0.5% topical levofloxacin, 0.5% cefmenoxime hemihydrochloride and ofloxacin ophthalmic ointment were used. In addition, subconjunctival injections of vancomycin hydrochloride (25 mg in 0.5 ml) and ceftazidime (100 mg in 0.5 ml) were used. For intracameral injections, vancomycin hydrochloride (1 mg in 0.1 ml) and ceftazidime (2.25 mg in 0.1 ml) were used. For intravitreal injections, vancomycin hydrochloride (1 mg in 0.1 ml) and ceftazidime (2.25 mg in 0.1 ml) were used. For intravitreal irrigation with vitreous surgery, vancomycin hydrochloride (100 mg in 500 ml) and ceftazidime (200 mg in 500 ml) were used. The types and doses of systemic antibiotics were used at the discretion of the local physician. Either systemic or local corticosteroids were used after sufficient antibiotic therapy and were also used at the discretion of the local physician. The predetermined protocol is summarized in Table 1 . Antibiotics other than those previously mentioned were administered when the predetermined protocol was found to be ineffective. More potent drugs were used based on bacterial cultures, and when there were special considerations, such as with patients who had allergic reactions.
In the present report, we describe the features, bacterial cultures and outcomes of infections when treated using the predetermined protocol. The study involved 21 patients with BRI in a cohort comprised of 1098 eyes of 1098 patients that were treated with trabeculectomy or with combined surgery with mitomycin C. For the calculation of logMAR, counting fingers was considered as 0.004, hand motion as 0.002, light sensation as 0.001 and no light sensation as 0.0004. The analyses were conducted using the IBM SPSS statistical software for Windows, version 20.0 (IBM Japan, Tokyo, Japan) when necessary.
Results
Of the total of 21 patients with BRI, two patients were excluded from the study. One patient was excluded because an infection was noted and treated when the patient was abroad. She had recovered when the clinician examined her when she returned home . Another patient was excluded because of a violation of the predetermined protocol. Hence, we ○ indicates a case whose decimal VA decreased 2 lines or worse.
analysed a total of 19 patients. The characteristics of the patients' eyes with BRI are listed in Table 2 . Infection developed twice in one eye. Trabeculectomy was the last glaucoma surgery before infection in 17 eyes, and trabeculectomy combined with phacoemulsification/intraocular lens implantation was the last surgery in two eyes. There were 11 male patients and eight female patients. The right eye was affected in nine eyes (47%), and the left eye was affected in 10 eyes (53%). The logMAR was 0.623 AE 0.748 (mean AE SD; range, À0.079 to À3.000) before the infection developed. It was 1.054 AE 1.156 (range, À0.079 to À3.398) and 0.950 AE 1.168 (range, À0.079 to À3.398) at 6 and 12 months post-infection, respectively. Three eyes each were excluded from the VA analyses at both 6-and 12-month follow-ups because of missing data. Another patient was excluded from the 12-month follow-up because of a change of hospitals. Figures 1 and 2 show the relationships between preinfection and post-infection visual acuities. The postinfection logMAR was significantly worse (p = 0.011 and p = 0.041 at 6 and 12 months post-infection, respectively; Wilcoxon signed-rank test). In subgroup analyses involving only stage I infections, the post-infection logMAR did not change significantly at 6 months (p = 0.109) and 12 months (p = 0.500; Wilcoxon signed-rank test). In subgroup analyses involving only stage II infections, the post-infection logMAR did not change significantly at 6 months (p = 0.249) and 12 months (p = 0.465; Wilcoxon signed-rank test). We could not analyse the post-infection logMAR in stage III because the post-infection VA was only measured in four patients; however, the decimal VA decreased ≥2 lines in all four patients ( Table 2) .
The IOP was 10.2 AE 5.0 mmHg (mean AE SD; range, 3-22 mmHg) before the infection developed. It was 12.9 AE 5.2 mmHg (range, 5-24 mmHg) and 10.7 AE 4.7 mmHg (range, 3-18 mmHg) at 6 and 12 months after infection, respectively. One eye was excluded from the IOP analyses at post-infection because of enucleation. Another patient changed hospitals and was excluded from the 12-month followup. Figures 3 and 4 show the relationships between preinfection and postinfection IOPs. The IOP did not change significantly following BRI both at 6 and 12 months (p = 0.059 and p = 0.977 at 6 and 12 months post-infection, respectively; Wilcoxon signed-rank test). In subgroup analyses of only stage II and III infections, the IOP did not change significantly (p = 0.056 and p = 0.725 at 6 and 12 months post-infection, respectively; Wilcoxon signed-rank test).
The bleb was avascular before the onset of infection in 11 eyes (58%), partially avascular in seven eyes (37%), and vascular in one eye (5%). Bleb leakage was noticed before infection in five eyes (26%) and was not noticed in 14 eyes (74%).
Discussion
Bleb-related infection (BRI) is one of the most serious complications after trabeculectomy. The visual outcome of no light perception at 12 months after treatment for bleb-related endophthalmitis was 35% (Al-Turki et al. 2010) and only 10-13% of the eyes achieved 20/40 or better (Chen et al. 1997; Al-Turki et al. 2010) . Using univariate analyses, shorter intervals from the onset of symptoms and treatment and better initial were significantly positive predictors for good visual outcomes (Mac & Soltau 2003) , indicating that antibacterial therapy for the infection should be performed as soon as possible in suspected cases of BRI. Furthermore, the treatment choice may affect the final outcomes; however, the optimal treatment protocol has not yet been established. For those patients with blebitis only, without evidence of vitreous involvement or hypopyon, intensive treatment with topical antibiotics alone may be appropriate (Chiam et al. 2012; Witkin et al. 2015) . However, in a survey from the UK (Song et al. 2002) , it was reported that 23% of the respondents' ophthalmologists treated blebitis as endophthalmitis with intravitreal antibiotics, even when there was low anterior chamber activity. Furthermore, it was reported that intracameral vancomycin injection in patients undergoing phacoemulsification cataract surgery, which is used in the same manner as in stage II of BRI, rarely caused haemorrhagic occlusive vasculitis (Busbee et al. 2004) . The results of different studies that compared the outcomes of initial pars plana vitrectomy and intravitreal injection versus initial tap and intravitreal injection were both consistent and contradictory (Chen et al. 1997; Mac & Soltau 2003; Al-Turki et al. 2010; Leng et al. 2011 ). To minimize delayed or excessive treatments, we determined a treatment protocol according to the stage of BRI before starting the CBIITS and evaluated the efficacy of the predetermined treatment protocol.
The present study showed that VA was significantly worse following BRI and bleb-related endophthalmitis (i.e. stage III infections), but the IOP did not increase after infection in a large-scale 5-year prospective study involving trabeculectomy and trabeculectomy combined with phacoemulsification/ intraocular lens implantation. One of the reasons we were unable to show an IOP increase is that the number of BRI cases was smaller than anticipated. We estimated the annual infection rate at approximately 1% when planning this prospective, multicentre cohort study, referring to previous studies of BRI (Greenfield et al. 1996; Higginbotham et al. 1996; DeBry et al. 2002) . However, the actual BRI incidence was lower and found to be 2.2 AE 0.5% (calculated 
20/400 or better (52%).
A total of 9 eyes (13%) were eventually eviscerated or enucleated.
The mean IOP at the final follow-up; 12 mmHg (range, 0-32; SD, 6.5).
BAE = bleb-associated endophthalmitis; BRI = bleb-related infection; HM = hand motion; IOP = intraocular pressure; LP = light perception; NLP = no light perception; PPV = pars plana vitrectomy; VA = visual acuity.
cumulative incidence AEstandard error; Kaplan-Meier survival analysis) at the 5-year follow-up (Yamamoto & Kuwayama 2011) . It was also 1.1 AE 0.3% for endophthalmitis. Thus, the smaller number of patients made the interpretation of the results more difficult.
In the present study, the logMAR was 0.623 AE 0.748 (mean AE SD), 1.054 AE 1.156 and 0.950 AE 1.168 for preinfection, at 6, and 12 months postinfection, respectively. A study by the Japan Glaucoma Society Survey of Bleb-related Infection (JGSSBI) (Yamamoto et al. 2013a) , which was another prospective study by the Japan Glaucoma Society, reported a total of 122 infections at various stages involving logMAR values of 0.634 AE 0.955, 1.007 AE 1.189 and 1.138 AE 1.263, respectively. There were no significant differences between the two studies.
Several authors reported visual outcomes after resolution of bleb-related endophthalmitis. Greenfield et al. (1996) reported worsening of logMAR, with an average of 1.42. Song et al. (2002) reported that 53% of patients achieved a VA better than or equal to 20/400, and cited previous studies reporting that a total of 41% achieved this level of VA based on four previous reports (Mandelbaum et al. 1985; Higginbotham et al. 1996; Ciulla et al. 1997; Kangas et al. 1997) . Our data showed that the average logMAR change was 0.831 with three eyes achieving at least 20/400 out of four stage III infections. Because of the paucity of data, the visual recovery achieved by our predetermined treatment protocol was inconclusive. However, Table 3 shows that our results using the predetermined treatment protocol were comparable to other reports.
There was no significant change in the IOP between the pre-and post-infection eyes in the present study. The JGSSBI (Yamamoto et al. 2013a) reported that IOP increased significantly from 9.9 AE 3.8 mmHg (mean AE SD) at preinfection to 11.5 AE 4.9 mmHg and 11.8 AE 5.2 mmHg at 6 months and 12 months post-infection, respectively. This tendency was more prominent in stage III infections than stage I and II infections. Chen et al. (1997) reported relatively good IOP control during bleb infection without clinical vitreous involvement. Greenfield et al. (1996) reported an average IOP increase of 1.2 mmHg following bleb-related endophthalmitis. Song et al. (2002) reported that the IOP was uncontrolled in 11% of cases after resolution of blebrelated endophthalmitis. Although no significant effects on the IOP following BRI were found, it is not known whether our predetermined treatment protocol significantly contributed to better results because of the small number of BRI patients analysed.
The bacterial cultures were positive in 21% of the cases in the present study. The JGSSBI (Yamamoto et al. 2013b) reported that Staphylococcus species were the most frequently isolated bacteria (41%), followed by Streptococcus species (32%), with a positive culture percentage of 49.7%. Other studies (Chen et al. 1997; Waheed et al. 1998; Al-Turki et al. 2010) reported that the major causative bacteria were Streptococcus species, Staphylococcus species, Pseudomonas aeruginosa, Moraxella, Enterococcus and Haemophilus influenzae. Jacobs et al. (2011) reported a positive culture percentage of 63% in bleb-associated endophthalmitis. The percentage of positive cultures was lower in the present study than that in the JGSSBI study (Yamamoto et al. 2013b ; p = 0.018, versus the present study; chi-square test), which cannot be explained. However, the isolates of the present study were consistent with previous reports (Chen et al. 1997; Waheed et al. 1998; Al-Turki et al. 2010; Jacobs et al. 2011; Yamamoto et al. 2013b) .
The patients' backgrounds in the present study were similar to previous studies. For example, the JGSSBI study (Yamamoto et al. 2013b) reported a mean age of 59.3 years with 68% of the cases being male (p = 0.379, versus the present study; chi-square test). The distribution of infection stages was also similar to the JGSSBI study (p = 0.499; chi-square test).
There are some limitations in the present study. First, the number of BRI patients was small. The infection patients were taken from a cohort comprising a total of 1,098 eyes with filtering surgery, with an average follow-up of 51.9 months. Thus, as discussed previously, the paucity in the number of BRI patients resulted from not knowing the actual incidence of infection before the study, although this issue was successfully elucidated in the previous CBIITS . Second, there were some missing visual acuities.
Third, the results cannot be extrapolated to other ethnic groups because the study was only conducted in Japan. Fourth, the percentage of positive cultures was very low.
The VA worsened after BRI in stage III when treated by the predetermined treatment protocol. Based on the present study, as well as previous studies, BRI is still an important clinical condition following glaucoma filtering surgery, even with immediate intensive treatment consisting of massive antibacterial drugs and vitreous surgery when necessary. Further studies may still prove the efficacy of intensive treatment for BRI. Presently, we recommend an early consultation and patient education regarding this condition, as well as additional preventative measures such as repair of bleb leakage for better prognoses of eyes with a filtering bleb.
